PRESS RELEASES

Date Title View
Toggle Summary Chimerix CEO George Painter, Ph.D., to Speak at Institute of Medicine Workshop
- CMX001 data will also be presented in a poster session
View HTML
Toggle Summary Chimerix’s Antiviral CMX001 Abstract Selected for an Oral Presentation at EBMT's Annual Meeting
- CMX001 data will also be presented in a poster session
View HTML
Toggle Summary Chimerix to Present at Two Upcoming Investor Conferences
Chimerix to Present at Two Upcoming Investor Conferences Chimerix to Present at Two Upcoming Investor Conferences RESEARCH TRIANGLE PARK, NC, November 12, 2009 – Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases,
View HTML
Toggle Summary Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
View HTML
Toggle Summary Chimerix Raises $16.1 Million in Series E Financing
- CMX001 data will also be presented in a poster session
View HTML
Toggle Summary Chimerix’s Antiviral CMX001 Abstract Selected for an Oral Presentation at EBMT's Annual Meeting
- CMX001 data will also be presented in a poster session
View HTML
Toggle Summary Chimerix Joins International Network of Organizations to Cure Malaria
Chimerix Joins International Network of Organizations to Cure Malaria Chimerix Joins International Network of Organizations to Cure Malaria RESEARCH TRIANGLE PARK, NC, April 2, 2009 - Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that
View HTML
Toggle Summary Chimerix Completes Phase I Study And Initiates A Phase II Multi-Dose Clinical Trial For CMX001
Chimerix Completes Phase I Study And Initiates A Phase II Multi-Dose Clinical Trial For CMX001 - CMX001 is an Orally Available Broad Spectrum Antiviral Being Investigated for the Treatment of dsDNA Viruses Including Smallpox, BK Virus, CMV and Adenovirus - RESEARCH TRIANGLE PARK, NC, January 6,
View HTML
Toggle Summary Chimerix’s Antiviral CMX001 Abstract Selected for an Oral Presentation at EBMT's Annual Meeting
- CMX001 data will also be presented in a poster session
View HTML
Toggle Summary Chimerix Initiates A Multi-Dose Clinical Trial Of The Company’s Lead Compound, CMX001, For The Treatment For Smallpox Infection
Chimerix Initiates A Multi-Dose Clinical Trial Of The Company’s Lead Compound, CMX001, For The Treatment For Smallpox Infection RESEARCH TRIANGLE PARK, NC, December 11, 2007 - Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that the
View HTML